Immunosuppressive therapy of systemic lupus erythematosus associated peripheral neuropathy: A systematic review

Abstract

Introduction

Peripheral neurologic manifestations may be associated with most of the collagen vascular diseases including systemic lupus erythematosus (SLE), yet most of the times it is not clear what therapy should be prescribed. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations suggest the use of glucocorticoids and immunosuppressive agents for the treatment of SLE associated peripheral neuropathy (PN) (strength of statement A, category of evidence 1), however these recommendations are based on studies that did not focus specifically on PN but rather on neuropsychiatric manifestations of SLE out of which only one was a randomized controlled clinical trial that included 7 patients with peripheral neuropathy. The objective of this systematic review is to determine whether the pathogenic treatments (corticosteroids, immunosuppressive agents, intravenous immunoglobulins, plasmapheresis) are effective for SLE associated PN.

Methods

We searched MEDLINE for all the studies that included the pathogenic treatment of SLE associated PN. The purpose was to identify randomized clinical trials, and in the absence of these, we included observational studies and case reports or case series.

Results

The search returned only retrospective case reports or case series. Only one prospective study, a randomized controlled study, was focused on neuropsychiatric SLE and included few patients with PN (7). Some studies reported cases of PN responsive to glucocorticoids (GC), cyclophosphamide (CYC), rituximab (RTX), azathioprine (AZA), plasmapheresis (PPH), intravenous immunoglobulin (IVIG), mycophenolate mofetil (MMF) or different combinations of these immunosuppressive agents, whereas others noticed effectiveness of sequential treatments (i.e. administration of a therapeutic agent after another single agent or a combination of agents had previously failed). Many studies did not mention how the outcomes were objectively measured.

Conclusions

There are no interventional studies dedicated to the SLE associated PN, only retrospective case reports or case series which not only did they show contradictory results, but they also represent the lowest level of evidence. There is a strong need for new analytical studies dedicated to SLE associated PN.

Protocol registered with PROSPERO (number CRD42019121748).

Keywords

Systemic lupus erythematosus neuropsychiatric lupus peripheral neuropathy immunosuppressive agents plasmapheresis vasculitis

Get full access to this article

View all access options for this article.

References

Alarcon

Scofield

Reinlib

Cooper

GS.

Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257–268.

Aringer M, Costenbader K, Daikh D, et al. European league against rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Arthrit Rheumatol 2019; 71: 1400–1412.

Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of systemic lupus international collaborating clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074–2082.

Hanly JG, Li Q, Su L, et al. Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study. Arthritis & rheumatology 2020; 72: 67–77.

Bortoluzzi A, Piga M, Silvagni E, et al. Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus 2019; 28: 465–474.

Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Annals of the Rheumatic Diseases 2005; 64: 620–625.

Stojanovich

Kostich

Dzjolich

Neuropsychiatric lupus favourable response to low dose iv cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12: 3–7.

Neuwelt

CM.

The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003; 7: 173–182.

10.

Bartolucci

Bréchignac

Cohen

Le Guern

Guillevin

Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 2007; 16: 817– 822.

11.

Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin – clinical and serologic response. Lupus 1999; 8: 705–712.

12.

Milstone

Meyers

Elia

Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 2005; 24: 394–397.

13.

Dekkers OM, Egger M, Altman DG and Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med 2012; 156: 37–40.

14.

Fargetti S, Ugolini-Lopes MR, Pasoto SG, et al. Short-and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 2019.

15.

Rivière E, Aubart FC, Maisonobe T, et al. Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. J Neurol 2017; 264: 1218–1226.

16.

Navinan MR, Piranavan P, Akram AUA, Yudhishdran J, Kandeepan T and Kulatunga A. Sensory neuronopathy complicating systemic lupus erythematosus: a case report. J Med Case Rep 2014; 8: 141.

17.

Yukawa S, Tahara K, Shoji A, Hayashi H and Tsuboi N. Acute pan-dysautonomia as well as central nervous system involvement and peripheral neuropathies in a patient with systemic lupus erythematosus. Modern Rheumatology 2008; 18: 516–521.

18.

Enevoldson

Wiles

CM.

Severe vasculitic neuropathy in systemic lupus erythematosus and response to cyclophosphamide. J Neurol Neurosurg Psychiatry 1991; 54: 468–469.

19.

Hughes RA, Cameron JS, Hall SM, Heaton J, Payan J and Teoh R. Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus – nerve biopsy and response to plasma exchange. J Neurol 1982; 228: 239–247.

20.

Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus 2016; 25: 627–636.

21.

Zuberbuhler P, Young P, León LC, et al. Sensory neuronopathy. Its recognition and early treatment. Medicina (B Aires) 2015; 75: 297–302.

22.

Roccatello D, Sciascia S, Rossi D, et al. Intensive shortterm treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dialysis Transplant 2011; 26: 3987–3992.

23.

Cañas C, Tobón GJ, Granados M and Fernández L. Diffuse alveolar hemorrhage in Colombian patients with systemic lupus erythematosus. Clin Rheumatol 2007; 26: 1947–1949.

24.

Harscher S, Rummler S, Oelzner P, et al. Selektive immunadsorption bei neurologischen komplikationen eines systemischen lupus erythematodes. Nervenarzt 2007; 78: 441–444.

25.

Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 2005; 1051: 779–786.

26.

Kasitanon N, Louthrenoo W, Piyasirisilp S, Sukitawu W and Wichainun R. Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2002; 20: 179–185.

27.

Lino AM, Hirata MTA, Ba≖ta AM, Tsanaclis AM, Scaff M and Marchiori PE. Intravenous therapy with methylprednisolone and cyclophosphamide in vasculitis of peripheral nervous system: evaluation of eight patients. Arq Neuropsiquiatr 1998; 56: 274–280.

28.

Rosenbaum

Simpson

Neuwelt

CM.

Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 1997; 81: 130–132.

29.

Neuwelt CM, Lacks S, Kaye BR, Ellman JB and Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32–41.

30.

Kissel JT, Slivka AP, Warmolts JR and Mendell JR. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol 1985; 18: 251–257.

31.

Trautmann F, Krämer G, Poralla T, Eckhardt R, Arnold W and Meyer zum Büschenfelde KH. Systemic lupus erythematosus. Brown-Sequard syndrome, spinal ataxia and peripheral polyneuropathy as the sole manifestations. Dtsch Med Wochenschr 1984; 109: 1028–1032.

32.

Humă AC, Kecskeş, EM, Tulbă D, Bălănescu P and Băicuş C. Immunosuppressive treatment for peripheral neuropathies in Sjogren’s syndrome – a systematic review. Roman J Intern Med 2020; 58: 5–12.